At this time, the subtype classifications most often used in clinical settings are based on the commonly measured tumor markers estrogen receptor (ER), progesterone receptor (PR), and HER2/neu (HER2), which offer imperfect but practical surrogates for genomic profiling [5]. This evidence concerns the gene ERBB2 and neoplasm.